Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis

Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-mod...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2018
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/22632
Acceso en línea:
https://doi.org/10.1016/j.msard.2018.09.014
https://repository.urosario.edu.co/handle/10336/22632
Palabra clave:
Alemtuzumab
Beta interferon
Daclizumab
Fingolimod
Glatiramer
Placebo
Teriflunomide
Beta interferon
Crotonic acid derivative
Immunologic factor
Teriflunomide
Toluidine derivative
Article
Drug efficacy
Drug safety
Human
Hypertransaminasemia
Liver function
Liver function test
Meta analysis
Multiple sclerosis
Systematic review
Toxic hepatitis
Treatment outcome
Comparative study
Drug effect
Liver
Multiple sclerosis
Toxic hepatitis
Chemical and drug induced liver injury
Crotonates
Humans
Immunologic factors
Interferon-beta
Liver
Multiple sclerosis
Toluidines
Interferon ?
Liver safety profile
Multiple sclerosis
Teriflunomide
Rights
License
Abierto (Texto Completo)
Description
Summary:Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN ? (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN ? (OR 1.09, 95% CI 0.02–2.16). Conclusions: There were no significant difference when comparing IFN ? and teriflunomide in terms of liver failure or elevation of transaminases. © 2018